512 Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumors

• Igor Puzanov,
• Jason Luke,
• Anthony Olszanski,
• Dan Lu,
• Stella Martomo,
• Jeegar Patel,
• Christos Fountzilas,
• Lee Rosen,
• Adrian Hackett,
• Olivier Schueller,
• David Eiznhamer,
• Alessandro Mora,
• Miranda Ross

Affiliations

Igor Puzanov

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Jason Luke

1University of Iowa, Iowa City, IA, USA

Anthony Olszanski

4Fox Chase Cancer Center, Philadelphia, PA, USA

Dan Lu

1Kadmon Corporation, New York, NY, USA

Stella Martomo

2Kadmon Pharmceuticals, LLC, New York, NY, USA

Jeegar Patel

2Kadmon Pharmceuticals, LLC, New York, NY, USA

Christos Fountzilas

11Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Lee Rosen

4UCLA Division of Hematology-Oncology, Los Angeles, CA, USA

Adrian Hackett

5Kadmon Corporation, NEW YORK, NY, USA

Olivier Schueller

5Kadmon Corporation, NEW YORK, NY, USA

David Eiznhamer

5Kadmon Corporation, NEW YORK, NY, USA

Alessandro Mora

5Kadmon Corporation, NEW YORK, NY, USA

Miranda Ross

5Kadmon Corporation, NEW YORK, NY, USA